These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 617785)

  • 61. An agarose plate method for detecting alloantisera to coagulant factor IX and factor IX antigen.
    Reisner HM; Strand EA; Chung KS; Roberts HR
    Br J Haematol; 1980 Feb; 44(2):313-21. PubMed ID: 7378302
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bovine factor IX (Christmas factor).
    Fujikawa K; Davie EW
    Methods Enzymol; 1976; 45():74-83. PubMed ID: 1012029
    [No Abstract]   [Full Text] [Related]  

  • 63. Characterisation of factor IX with a glycine-to-valine missense mutation at residue 190 in a patient with severe haemophilia B.
    Kao CY; Lin CN; Yang YL; Hamaguchi N; Yang SJ; Shen MC; Kao JT; Lin SW
    Thromb Haemost; 2011 Apr; 105(4):616-26. PubMed ID: 21301787
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Laboratory prediction of the carrier state in hemophilia B: role of replication of assays.
    Lipworth L; Tiarks CY; Rice CA; Pechet L
    Am J Clin Pathol; 1979 Dec; 72(6):1000-4. PubMed ID: 391020
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of age on factor IX levels in symptomatic carriers of Haemophila B Leyden.
    Hildyard C; Keeling D
    Br J Haematol; 2015 May; 169(3):448-9. PubMed ID: 25382638
    [No Abstract]   [Full Text] [Related]  

  • 66. Recombinant factor IX.
    White GC; Beebe A; Nielsen B
    Thromb Haemost; 1997 Jul; 78(1):261-5. PubMed ID: 9198163
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Identification of haemophilia B patients with mutations in the two calcium binding domains of factor IX: importance of a beta-OH Asp 64----Asn change.
    Winship PR; Dragon AC
    Br J Haematol; 1991 Jan; 77(1):102-9. PubMed ID: 1998585
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B.
    Chang JY; Monroe DM; Stafford DW; Brinkhous KM; Roberts HR
    J Clin Invest; 1997 Aug; 100(4):886-92. PubMed ID: 9259588
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Complete deletion of factor IX gene and inhibition of factor IX activity in a labrador retriever with hemophilia B.
    Brooks MB; Gu W; Ray K
    J Am Vet Med Assoc; 1997 Dec; 211(11):1418-21. PubMed ID: 9394892
    [TBL] [Abstract][Full Text] [Related]  

  • 70. T296----M, a common mutation causing mild hemophilia B in the Amish and others: founder effect, variability in factor IX activity assays, and rapid carrier detection.
    Ketterling RP; Bottema CD; Koeberl DD; Ii S; Sommer SS
    Hum Genet; 1991 Jul; 87(3):333-7. PubMed ID: 1864609
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Detection of carriers of haemophilia B.
    Orstavik KH; Veltkamp JJ; Bertina RM; Hermans J
    Br J Haematol; 1979 Jun; 42(2):293-301. PubMed ID: 465373
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Preparation of factor IX deficient human plasma by immunoaffinity chromatography using a monoclonal antibody.
    Goodall AH; Kemble G; O'Brien DP; Rawlings E; Rotblat F; Russell GC; Janossy G; Tuddenham EG
    Blood; 1982 Mar; 59(3):664-70. PubMed ID: 7059674
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The genetic heterogeneity of hemophilia B.
    Brown PE; Hougie C; Roberts HR
    N Engl J Med; 1970 Jul; 283(2):61-4. PubMed ID: 5420360
    [No Abstract]   [Full Text] [Related]  

  • 74. Characterization of factor IX defects in hemophilia B patients.
    Thompson AR; Chen SH
    Methods Enzymol; 1993; 222():143-69. PubMed ID: 8412791
    [No Abstract]   [Full Text] [Related]  

  • 75. Factor IX gene analysis in 70 unrelated patients with haemophilia B: description of 13 new mutations.
    Attali O; Vinciguerra C; Trzeciak MC; Durin A; Pernod G; Gay V; Ménart C; Sobas F; Dechavanne M; Négrier C
    Thromb Haemost; 1999 Nov; 82(5):1437-42. PubMed ID: 10595634
    [TBL] [Abstract][Full Text] [Related]  

  • 76. An immunological method for detection of the carrier of hemophilia B.
    Matsuoka M; Ito M; Takahashi K; Sakuragawa N
    Thromb Haemost; 1976 Nov; 36(2):441-50. PubMed ID: 1036844
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Factor IX Denver, ASN 346-->ASP mutation resulting in a dysfunctional protein with defective factor VIIIa interaction.
    Lefkowitz JB; Nuss R; Haver T; Jacobson L; Thompson AR; Manco-Johnson M
    Thromb Haemost; 2001 Sep; 86(3):862-70. PubMed ID: 11583320
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Biochemical and in vivo properties of high purity factor IX concentrates.
    Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
    Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hemophilia B (factor IXSeattle 2) due to a single nucleotide deletion in the gene for factor IX.
    Schach BG; Yoshitake S; Davie EW
    J Clin Invest; 1987 Oct; 80(4):1023-8. PubMed ID: 2821070
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Expression and Characterization of Gly-317 Variants of Factor IX Causing Variable Bleeding in Hemophilia B Patients.
    Lu Q; Yang L; Manithody C; Wang X; Rezaie AR
    Biochemistry; 2015 Jun; 54(24):3814-21. PubMed ID: 26023895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.